Last reviewed · How we verify
SPMC 2
SPMC 2 is a small molecule that targets the Sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.
SPMC 2 is a small molecule that targets the Sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses. Used for Multiple sclerosis.
At a glance
| Generic name | SPMC 2 |
|---|---|
| Also known as | Picolight(Pharmbio korea, Seoul, Korea) |
| Sponsor | Korea University Anam Hospital |
| Drug class | Sphingosine-1-phosphate receptor 1 (S1PR1) modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 3 |
Mechanism of action
By binding to S1PR1, SPMC 2 inhibits the migration of lymphocytes to lymphoid organs, thereby reducing inflammation and modulating immune responses. This mechanism of action is thought to be beneficial in the treatment of autoimmune diseases.
Approved indications
- Multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- PEG-Asc Vs. SPMC for Bowel Preparation in Capsule-based Procedures (NA)
- Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC) (PHASE4)
- Compare Polyethylene Glycol and Sodium Picosulfate Alone or Combined (NA)
- Impact of Time Intervals of Preparation on Quality and Tolerance of the Bowel Preparation (PHASE4)
- A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods (PHASE3)
- A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPMC 2 CI brief — competitive landscape report
- SPMC 2 updates RSS · CI watch RSS
- Korea University Anam Hospital portfolio CI